Search results
Results from the WOW.Com Content Network
The editor in chief of the Journal of Immunotoxicology is Mitchell D. Cohen (New York University School of Medicine, Tuxedo, New York, United States. [1] According to the Journal Citation Reports it received an impact factor of 2.054, ranking it 55th out of 87 journals in the category "Toxicology". [2]
Human Immunology is a monthly peer-reviewed medical journal published by Elsevier in behalf of the American Society for Histocompatibility and Immunogenetics.It contains original research articles, review articles, and brief communications on the subjects of immunogenetics, cellular immunology and immune regulation, and clinical immunology.
The journal was established in 1929 as the Journal of Allergy and obtained its current name in 1971. [2] [3] The name change was purportedly related to a change in the attitude among physicians about the breadth of applicability of the term "allergy". [4] The journal has been published under the Mosby imprint since its inception. [2] [3]
The Annual Review of Immunology is a peer-reviewed scientific journal published by Annual Reviews. It releases an annual volume of review articles relevant to the field of immunology . It was first published in 1983 with inaugural editor William E. Paul ; Paul remained editor for the journal's first thirty years.
Expert Review of Clinical Immunology is a monthly peer-reviewed medical journal covering all aspects of clinical immunology. It is part of the Expert Review series, published by Informa. The editors-in-chief are Thomas Forsthuber (University of Texas at San Antonio) and Timothy Radstake (University Medical Center Utrecht). The journal was ...
This article about an immunology journal is a stub. You can help Wikipedia by expanding it. See tips for writing articles about academic journals. Further suggestions might be found on the article's talk page.
Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, also sends Crohn's disease into clinical remission, new findings suggest.
According to the Journal Citation Reports it received in 2014 an impact factor of 1.203, ranking it 133rd out of 148 journals in the category "Immunology", [3] ranking it 204th out of 254 journals in the category "Pharmacology & Pharmacy" [4] and ranking it 73rd out of 87 journals in the category "Toxicology".